176 related articles for article (PubMed ID: 35864117)
1. Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer.
Zhou X; Zhou R; Rao X; Hong J; Li Q; Jie X; Wang J; Xu Y; Zhu K; Li Z; Wu G
Cell Death Dis; 2022 Jul; 13(7):636. PubMed ID: 35864117
[TBL] [Abstract][Full Text] [Related]
2. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
[TBL] [Abstract][Full Text] [Related]
3. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
4. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.
Hassanein M; Qian J; Hoeksema MD; Wang J; Jacobovitz M; Ji X; Harris FT; Harris BK; Boyd KL; Chen H; Eisenberg R; Massion PP
Int J Cancer; 2015 Oct; 137(7):1587-97. PubMed ID: 25821004
[TBL] [Abstract][Full Text] [Related]
5. Circ_0000808 promotes the development of non-small cell lung cancer by regulating glutamine metabolism via the miR-1827/SLC1A5 axis.
Cai Y; Dong Z; Wang J
World J Surg Oncol; 2022 Oct; 20(1):329. PubMed ID: 36192755
[TBL] [Abstract][Full Text] [Related]
6. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
7. hsa_circ_0000518 Facilitates Non-Small-Cell Lung Cancer Progression via Moderating miR-330-3p and Positively Regulating SLC1A5.
Lv H; Shi Z; Sui A; Zhang Y; Peng L; Wang M; Zhang F
J Immunol Res; 2022; 2022():4996980. PubMed ID: 35874898
[TBL] [Abstract][Full Text] [Related]
8. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
[TBL] [Abstract][Full Text] [Related]
9. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
10. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming.
Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
[TBL] [Abstract][Full Text] [Related]
11. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.
Hu X; Deng J; Yu T; Chen S; Ge Y; Zhou Z; Guo Y; Ying H; Zhai Q; Chen Y; Yuan F; Niu Y; Shu W; Chen H; Ma C; Liu Z; Guo F
Gastroenterology; 2019 Mar; 156(4):1098-1111. PubMed ID: 30452920
[TBL] [Abstract][Full Text] [Related]
12. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
13. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
14. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
15. Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.
Hu R; Li T; Hui K; Chen Z; Wang N; Wu X; Ge L; Zhou L
Mol Med Rep; 2020 Nov; 22(5):3935-3943. PubMed ID: 32901884
[TBL] [Abstract][Full Text] [Related]
16. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
[TBL] [Abstract][Full Text] [Related]
17. NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells.
Zeng C; Wu Q; Wang J; Yao B; Ma L; Yang Z; Li J; Liu B
Free Radic Biol Med; 2016 Dec; 101():236-248. PubMed ID: 27989748
[TBL] [Abstract][Full Text] [Related]
18. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
19. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport.
Duan Z; Zhou Z; Lu F; Zhang Y; Guo X; Gui C; Zhang H
Invest New Drugs; 2022 Oct; 40(5):977-989. PubMed ID: 35834041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
